A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration in Children with Asthma (6 to Less Than 12 Years of Age) - Trial 2017-002060-40
Access comprehensive clinical trial information for 2017-002060-40 through Pure Global AI's free database. This phase not specified trial is sponsored by Teva Branded Pharmaceutical Products R&D, Inc. and is currently status unknown. The study focuses on Asthma.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Teva Branded Pharmaceutical Products R&D, Inc.
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
a. The patient has any clinically significant medical history or current uncontrolled medical condition (treated or untreated) that would interfere with the study schedule or procedures, interpretation of results, or compromise the patient’s safety. This includes clinically uncontrolled asthma, in the judgment of the investigator.
ICD-10 Classifications
Data Source
EU Clinical Trials Register
2017-002060-40
Non-Device Trial